Literature DB >> 8190283

Intractable nonlesional epilepsy of temporal lobe origin: lateralization by interictal SPECT versus MRI.

C R Jack1, B P Mullan, F W Sharbrough, G D Cascino, M F Hauser, K N Krecke, P H Luetmer, M R Trenerry, P C O'Brien, J E Parisi.   

Abstract

We performed a retrospective study of 53 consecutive "nonlesional" temporal lobectomy patients to assess the relative utility of MRI versus interictal single-photon emission computed tomography (SPECT) in this patient population. We compared the seizure lateralizing properties of MRI and SPECT using multiple blinded expert reviewers for both SPECT and MRI with a test-retest reviewer paradigm and measurements of hippocampal volume from MRI. The criterion standard for seizure lateralization was satisfactory postoperative seizure control (n = 43). The rate of correct seizure lateralization was significantly greater for MRI than for SPECT (p < or = 0.01), and the rate of incorrect lateralization was significantly less for MRI than for SPECT. The most accurate MRI measure was hippocampal volume measurements, which correctly lateralized the seizures in 86.0% of cases. The correct lateralization rate for SPECT was 45.4%. The MRI and SPECT studies tended to be noncomplementary with respect to seizure lateralization, and SPECT was likely to give an incorrect or indeterminate result in patients who were not lateralized by MRI. Concordant MRI-EEG lateralization was a strong predictor of satisfactory postoperative seizure control, while no relationship between postoperative seizure control and SPECT findings was present.

Entities:  

Mesh:

Year:  1994        PMID: 8190283     DOI: 10.1212/wnl.44.5.829

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Non-invasive investigations successfully select patients for temporal lobe surgery.

Authors:  C Kilpatrick; M Cook; A Kaye; M Murphy; Z Matkovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

2.  Comparison of [18F]FDG-PET, [99mTc]-HMPAO-SPECT, and [123I]-iomazenil-SPECT in localising the epileptogenic cortex.

Authors:  S Lamusuo; H M Ruottinen; J Knuuti; R Härkönen; U Ruotsalainen; J Bergman; M Haaparanta; O Solin; E Mervaala; U Nousiainen; S Jääskeläinen; A Ylinen; R Kälviäinen; J K Rinne; M Vapalahti; J O Rinne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

3.  Multimodal coregistration in patients with temporal lobe epilepsy--results of different imaging modalities in lateralization of the affected hemisphere in MR imaging positive and negative subgroups.

Authors:  M T Doelken; G Richter; H Stefan; A Doerfler; A Noemayr; T Kuwert; O Ganslandt; C H Nimsky; T Hammen
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

4.  Validation of ictal single photon emission computed tomography with depth encephalography and epilepsy surgery.

Authors:  Vijay M Thadani; Alan Siegel; Petra Lewis; Adrian M Siegel; Barbara C Jobst; Karen L Gilbert; Terrance M Darcey; David W Roberts; Peter D Williamson
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

Review 5.  Advances in neuroimaging: management of partial epileptic syndromes.

Authors:  Barbara Schäuble; Gregory D Cascino
Journal:  Neurosurg Rev       Date:  2003-08-22       Impact factor: 3.042

Review 6.  1H MR spectroscopy in patients with mesial temporal epilepsy.

Authors:  M Hájek; M Dezortová; V Komárek
Journal:  MAGMA       Date:  1998-12       Impact factor: 2.310

Review 7.  Presurgical evaluation and surgical treatment of medically refractory epilepsy.

Authors:  Adrian M Siegel
Journal:  Neurosurg Rev       Date:  2003-10-28       Impact factor: 3.042

8.  Clinical validation of automated hippocampal segmentation in temporal lobe epilepsy.

Authors:  Peter N Hadar; Lohith G Kini; Carlos Coto; Virginie Piskin; Lauren E Callans; Stephanie H Chen; Joel M Stein; Sandhitsu R Das; Paul A Yushkevich; Kathryn A Davis
Journal:  Neuroimage Clin       Date:  2018-10-10       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.